QNCX
Quince TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The remaining upside case is no longer tied to eDSP development after Quince said the Phase 3 NEAT study missed primary and key secondary endpoints and that it would cease clinical development, preserve cash, and explore options; upside now rests on whether the cleaned-up balance sheet and strategic review produce a value-accretive transaction [#PR-2026-01-29][#PR-2026-03-30][#PR-2026-02-09].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Low coverage and thin liquidity can cause sharp price moves disconnected from intrinsic value.
Momentum
74
Value
41
Sentiment
50
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.90 · Bull $2.20 · Bear $0.35
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $5.50
Why
Momentum74 · Δ7d -
Value41 · Δ7d +0.1
Sentiment50 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
74
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
50
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 74.5 / Value 41.1 / Sentiment 49.8
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$17.12M
Beta
1.24
Shares Out
55.68M
P/E (TTM) · Derived
-0.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.37
Rev YoY
-
EPS YoY
-95.8%
Gross Margin
-
Op Margin
-
Net Debt
-$26.46M
Current Ratio
1.12
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology